Sign in
4

Changes in Ownership

Xenon Pharmaceuticals Inc. Filed Acc 0000950170-24-138629

Chief Financial Officer sold 18,709 shares at an average $41.21 ($770,912)

  • Chief Financial Officer gave up 6,625 shares (to pay taxes)
  • Chief Financial Officer acquired 25,334 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

AULIN SHERRY · Chief Financial Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2024-12-18 Exercise or conversion : show line 1 in the form +9,334 $9.44 $88,113 9,334 D
2024-12-18 Shares withheld for taxes : show line 2 in the form −2,135 $41.28 $88,133 7,199 D
2024-12-18 Sale : show line 3 in the form −7,199 $41.23 $296,815 0 D
2024-12-18 Exercise or conversion : show line 4 in the form +16,000 $11.58 $185,280 16,000 D
2024-12-18 Shares withheld for taxes : show line 5 in the form −4,490 $41.28 $185,347 11,510 D
2024-12-18 Sale : show line 6 in the form −11,510 $41.19 $474,097 0 D
Open-market sales · 18,709 sh · avg $41.21 · $770,912

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2024-12-18 Exercise or conversion : show line 7 in the form Stock Option (Right to Buy) −9,334 0 D
2024-12-18 Exercise or conversion : show line 8 in the form Stock Option (Right to Buy) −16,000 6,000 D
Loading xslF345X05/ownership.xml…